These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2166138)

  • 1. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
    Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
    J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration of pyridostigmine and effects in myastenia gravis.
    Chan K; Calvey TN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings].
    Calvey TN; Chan K
    Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
    Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
    Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
    Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
    Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
    Schumm F; Gaertner HJ; Wiatr G; Dichgans J
    Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
    Lundh H; Nilsson O; Rosén I
    Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pyridostigmine levels in patients with myasthenia gravis.
    Calvey TN; Chan K
    Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady state kinetics of pyridostigmine in myasthenia gravis.
    Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
    Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
    Davison SC; Hyman NM; Dehghan A; Chan K
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on neuromuscular function of acute chronic exposure to cholinesterase inhibitors in man and in the rat.
    Roberts DV; Taylor K; Wilson A
    J Physiol; 1971 Dec; 219(2):15P. PubMed ID: 4333825
    [No Abstract]   [Full Text] [Related]  

  • 14. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
    Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
    Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
    Riggs JE
    Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
    Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
    Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
    Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
    Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
    Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
    Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
    Henze T; Nenner M; Michaelis HC
    J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.